ERBB3 and cancer: Therefore, some catalytically defective RPTKs involved in tumorigenesis, such as PTK7, Erb-B2 receptor tyrosine kinase 3 (ErbB3), and EPH receptor A10 (EphA10), are considered target molecules for cancer therapy [3,4,5,6,7].